← Eichor
Study identifier: NCT07008092 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Prostaglandin-E Urinary Metabolite (PGE-M) as a Predictor of Acute Appendicitis in Children

Condition: Acute Appendicitis · Acute Appendicitis With Rupture · Abdominal Pain (AP)  ·  Sponsor: KBC Split

PhaseN/A
Planned participants100
Who can joinAll sexes, 5 Years to 17 Years
Healthy volunteersYes

About this study

Diagnosing acute appendicitis in children remains a clinical challenge, with delayed or incorrect diagnosis potentially leading to serious complications or unnecessary surgery. Prostaglandin E urinary metabolites (PGE-M) have been found elevated in various inflammatory conditions, but their diagnostic value in pediatric appendicitis is not well established. This study aims to assess the potential of PGE-M as a biomarker for acute appendicitis in children. The study will be conducted over 12 months and will include 100 children aged 5 to 17 years presenting with acute abdominal pain. In addition to routine laboratory tests, urinary PGE-M levels will be analyzed. The study involves minimal risk to participants

This description comes directly from the study's public registry record.

Talk to the study team

Tomislav Žuvela, Doctor of Medicine, MD  ·  +385919008148  ·  tomislav.zuvela29@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

University Hospital of SplitSplit, CroatiaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07008092